Today PVCT ranks # as SELL CANDIDATE.
Today PVCT ranks # as SELL CANDIDATE.

PVCT stock Provectus Pharmaceuticals, Inc

PVCT stock
Provectus Pharmaceuticals, Inc

April 24, 2019
Change -0.40%
Chart period: 2019-01-25 - 2019-04-24
VOLUME
Buy
TREND
Sell

MV LONG
Sell

MV SHORT
Sell

PIVOT
Sell

MACD
Sell

Will PVCT stock price go up or down on Fri, 26 Apr 2019?

Provectus Pharmaceuticals, Inc Forecast and Stock Analysis

Technical PVCT stock analysis for April 24, 2019.

Sell candidate since 2019-04-15 Loss -5.31%

Provectus Pharmaceuticals, Inc fell by -0.40% in the last day from $0.05 to $0.05 The price has fallen in 6 of the last 10 days and is down by -5.85% for this period. Volume has increased in the last day by 450 463 shares, but on falling prices. This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 581 497 shares bought and sold for approximately $29 016.70.

Close price at the end of the last trading day (Wednesday, 24th Apr 2019) of the PVCT stock was $0.05. This is 0.4% less than the trading day before Tuesday, 23rd Apr 2019.

During day the stock fluctuated 31.38% from a day low at $0.04 to a day high of $0.05.

30 day high of the PVCT stock price was $0.07 and low was $0.04.
90 day high was $0.07 and low was $0.04.
52 week high for the Provectus Pharmaceuticals, Inc - $0.08 and low - $0.03.

Trend

Provectus Pharmaceuticals, Inc lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -13.15% during the next 3 months and, with 90% probability hold a price between $0.04 and $0.05 at the end of this period.

Click here for today's Top 5 Trending Companies

Signals

There are few to none technical positive signals at the moment. Provectus Pharmaceuticals, Inc holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $0.05 and $0.05. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Thursday April 18, 2019, which indicates further falls until a new bottom pivot has been found. Provectus Pharmaceuticals, Inc gained volume on the last day, but on falling prices. In technical terms this is called divergence and may be an early warning. In some cases increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-off's". The very low volume increases the risk and reduces the other technical signals issued.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 46 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

Price: $0.05 Resistance: $0.06

Risk

This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.01 between high and low, or 31.38%. For the last week, the stock has had a daily average volatility of 11.80%.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

Overall risk:

Very Low Low Medium High Very High

Evaluation: Strong Sell Candidate

Provectus Pharmaceuticals, Inc holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Sell Candidate to a Strong Sell Candidate.

Today PVCT ranks # as SELL CANDIDATE.
Today PVCT ranks # as SELL CANDIDATE.